MSTN and obesity disorder: Conversely, elevated GDF8 (myostatin) exacerbates muscle loss and metabolic dysfunction, presenting a therapeutic target for obesity-related sarcopenia (Hittel et al. 2009; McPherron and Lee 1997; Rebbapragada et al. 2003).